Terumo Corp 2021 IR
The report highlights Terumo Corporation's performance and strategic initiatives for fiscal 2020, marking the company's 100th anniversary. Despite the challenges of the COVID-19 pandemic, the company minimized negative financial impacts through its balanced portfolio, achieving record-high domestic revenue in Japan. Terumo advanced its medical solutions across its Cardiac and Vascular, General Hospital, and Blood and Cell Technologies companies, while also establishing new greenhouse gas emissions reduction targets for fiscal 2030 approved by the Science Based Targets initiative.
Company: Terumo Corp
Sector: Manufacturing
Country: Japan
Year: 2021
Type: IR
Pages: 43
Back to company
Terumo Corp
Terumo Report
The report highlights Terumo Corporation's performance and strategic initiatives for fiscal 2020, marking the company's 100th anniversary. Despite the challenges of the COVID-19 pandemic, the company minimized negative financial impacts through its balanced portfolio, achieving record-high domestic revenue in Japan. Terumo advanced its medical solutions across its Cardiac and Vascular, General Hospital, and Blood and Cell Technologies companies, while also establishing new greenhouse gas emissions reduction targets for fiscal 2030 approved by the Science Based Targets initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women in Management
Employees